FILE PHOTO: A medical worker wearing personal protective equipment (PPE) works in the Intensive Care Unit (ICU) for coronavirus disease (COVID-19) patients at St. Marianna Medical University Hospital in Kawasaki, south of Tokyo, Japan May 4, 2020. REUTERS/Issei Kato
TOKYO (Reuters) - As nations race to develop treatments and vaccines for COVID-19, Japan has become a victim of its own success as slowing new infections has led to a shortage of patients to enroll in clinical trials.
Clinical trials are underway for more than a dozen potential vaccines, including at least six in China, but Japan's first human trials are expected to start next month.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
